Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

4 arms have a reported figure in this set.

Olutasidenib 1

Safusidenib (AB-218, DS-1001) 1

Safusidenib (AB-218, DS-1001)

Safusidenib 250 mg BID

250 mg · Single arm

IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)

confirmed objective response rate: 51.9%, median follow-up 38.8 months

J201 Phase 2 · NCT04458272

Vorasidenib 2

Vorasidenib

Vorasidenib 40 mg daily

40 mg · ITT

grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)

Comparator: placebo

objective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary

INDIGO · NCT04164901

Vorasidenib

Vorasidenib, non-enhancing glioma

Phase 1 doses · Single arm

recurrent non-enhancing IDH-mutant glioma (n = 22)

objective response rate: 18%, Phase 1

Vorasidenib Phase 1

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.